Clinical trial
IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)
NCT00136994 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00136994 |
|---|---|
| Title | IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study) |
| Official title | An Open Trial to Evaluate the Efficacy and Tolerability of Ziprasidone IM and Oral in Patients With Psychosis and Acute Agitation. |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Ziprasidone |
| Enrollment | 160 |
| Start date | Mar 1, 2003 |
| Completion | Nov 1, 2005 |
| First posted | Aug 29, 2005 |
| Last update posted | Feb 21, 2021 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: